Group A Streptococcal Vaccine
Group A streptococcus (GAS) diseases take 90% of streptococcal infection. GAS infection lead to over 111 million prevalent cases of streptococcal pyoderma, and 616 million new cases of GAS pharyngitis each year. Serious infections result when the organism spreads to contiguous sites or disseminates to deep tissues, which may be accompanied by suppurative complications,such as: cellulitis,erysipelas, necrotic fasciitis, sepsis etc. and nonsuppurative complications such as: acute rheumatic fever (ARF), which may further lead to acute heart disease and post-streptococcal glomerulonephritis (PSGN) etc.
Due to the structure variation of GAS pathogenicity-related M protein, thereare nearly 150 serotypes of GAS, but there is no cross immunity among them. This property makes it particularly difficult to treat and prevent the GAS infections. Thus, a vaccine capable of preventing GAS infections from different serotypes becomes a good solution.
Recombinant Staphylococcus Aureus vaccine (E. Coli.)
Staphylococcus aureus is a major pathogenic bacterium that causes hospital infection and community infection. Along with the long-term and widely use of antibiotics, bacteria resistance become moreserious day by day. As a typical case, Methicillin resistant Staphylococcus Aureus, MRSA, since founded in 1961, has become one of the hospital pathogenic bacteria that contribute most to the infections in global ICU, postoperative infection, burns and war injuries.
Tetanus Vaccine, Adsorbed
Tetanus vaccine is a detoxificated toxoid. Traditionally, the vaccine is produced by the cultivation of tetanus bacillus, with filtration methodology to collect the toxin, then have formaldehyde detoxification and purification etc.